Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Drammen – page 4

70 clinical trials in Drammen, Norway across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Drammen at a glance
70
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

70 trials in Drammen

Open in trial search

Coronary artery disease

Not yet recruiting

Continuing vs Stopping Acetylsalicylic Acid in Elderly Patients with Chronic Coronary Syndrome (Secondary Prevention): A Randomized Trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Vestre Viken HF

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Juvenile idiopathic arthritis

Not yet recruiting

Maintenance versus tapered TNF‑alpha inhibitor therapy (golimumab, etanercept, adalimumab) in children and adolescents with juvenile idiopathic arthritis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Oslo University Hospital HF

Non-small cell lung cancer

Not yet recruiting

Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Multiple sclerosis

Not yet recruiting

Study of Tenofovir Alafenamide as Add-on Treatment to Anti-CD20 Therapy in Multiple Sclerosis Patients to Reduce Neuronal Damage

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tenofovir Alafenamide
  • Sponsor:Oslo University Hospital HF

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Obesity+1

Not recruiting

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Primary adrenal insufficiency

Not recruiting

Study on Quality of Life in Patients Aged 16-80 with Primary Adrenal Insufficiency Using Hydrocortisone (Plenadren) and Cortisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Cortisone
  • Sponsor:Helse Bergen HF

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Drammen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on various cancer types, including pancreatic ductal cancer, small-cell lung cancer, and advanced melanoma. Studies evaluate new combination therapies and treatment approaches.

  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Colon Cancer Treatment

Research emphasizes improving survival rates and treatment efficacy through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into cardiovascular diseases and preventive treatments. Trials explore new approaches for stroke prevention and management of heart conditions.

  • Atrial Fibrillation Management
  • Stroke Prevention
  • Atherosclerotic Disease

Focus on developing innovative antiplatelet therapies and investigating cardiovascular safety in various patient populations.

03 Chronic Disease Management

Studies addressing chronic conditions including Multiple Sclerosis, Crohn's Disease, and Rheumatoid Arthritis. Trials evaluate new therapeutic approaches and drug combinations.

  • COPD Treatment
  • Inflammatory Conditions
  • Metabolic Disorders

Research aims to improve disease control and patient outcomes through innovative treatment strategies.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.